Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip

Biotechnology and Bioengineering

Volumn 110, Issue 2, 2013, Pages 597-608

  Choucha Snouber, Leila ^a   Aninat, Caroline ^b   Grsicom, Laurent ^c   Madalinski, Geoffrey ^d,e   Brochot, Céline ^f   Poleni, Paul Emile ^a   Razan, Florence ^c   Guillouzo, Christiane Guguen ^b   Legallais, Cécile ^a   Corlu, Anne ^b   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Université de Cergy Pontoise   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e CEA SACLAY   (France)

^f INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Co culture; Ifosfamide; Kidney; Liver; Micro fluidic biochips; PDMS

Indexed keywords

COCULTURE; IFOSFAMIDE; KIDNEY; MICRO FLUIDIC BIOCHIPS; PDMS;

ALDEHYDES; BIOASSAY; BIOCHIPS; BIOMOLECULES; CELLS; LIVER; MASS SPECTROMETRY; METABOLISM; METABOLITES; PHYSIOLOGY;

CELL CULTURE;

CHLOROACETALDEHYDE; IFOSFAMIDE;

ARTICLE; BIOCHIP; CALCIUM TRANSPORT; CELL COUNT; CELL PROLIFERATION; CELL STRUCTURE; COCULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROFLUIDICS; NEPHROTOXICITY;

ACETALDEHYDE; ANIMALS; CALCIUM; CELL CYCLE; CELL PROLIFERATION; CELL SHAPE; COCULTURE TECHNIQUES; DOGS; FLUORESCENT DYES; GENE EXPRESSION; HEP G2 CELLS; HUMANS; IFOSFAMIDE; KIDNEY; LIVER; MADIN DARBY CANINE KIDNEY CELLS; MICROFLUIDIC ANALYTICAL TECHNIQUES; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 84871719607     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24707     Document Type: Article

References (46)

1. Aleksa K, Halachmi N, Ito S, Koren G. 2005. A tubule cell model for ifosfamide nephrotoxicity. Can J Physiol Pharmacol 83: 499-508.
2. Aninat C, Piton A, Glaise D, Lecharpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34: 75-83.
3. Baudoin R, Corlu A, Griscom L, Legallais C, Leclerc E. 2007a. Trends in the development of micro fluidic cell biochips for in vitro hepatotoxicity. Toxicol In Vitro 21: 535-544.
4. Baudoin R, Griscom L, Monge M, Legallais C, Leclerc E. 2007b. Development of a renal microchip for in vitro distal tubule models. Biotechnol Progr 23: 1245-1253.
5. Baudoin R, Griscom L, Prot JM, Legallais C, Leclerc E. 2011. Behavior of HepG2/C3A cell cultures in a micro fluidic bioreactor. Biochem Eng J 53: 172-181.
6. Benesic A, Schwerdt G, Mildenberger S, Freudinger R, Gordjani N, Gekle M. 2005. Disturbed Ca2+-signaling by chloroacetaldehyde: A possible mechanism for chronic ifosfamide nephrotoxicity. Kidney Int 68: 2029-2041.
7. Bhatia SN, Yarmush ML, Toner M. 1997. Controlling cell interactions by micropatterning in co-cultures: Hepatocytes and 3T3 fibroblasts. J Biomed Mat Res 34: 189-199.
8. CEC. 1989. Commission of the European Communities/International program on chemical safety. Health signficance and early detection of nephrotoxicity. Toxicol Lett 46: 1-306.
9. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM. 2006. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biology 7: R100.
10. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, Corlu A. 2007. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45(4): 957-967.
11. Cerny T, Kupfer A. Stabilization and quantitative determination of the neurotoxic metabolite chloroacetaldehyde in the plasma of ifosfamide treated patients. In: Proceedings of the Fifth European Conference on Clinical Oncology, London, 1989, p 147.
12. Cerny T, Küpfer A. 1992. The enigma of ifosfamide encephalopathy. Ann Oncol 3: 679-681.
13. Choucha Snouber L, Letourneur F, Chafey P, Broussard C, Monge M, Legallais C, Leclerc E. 2012. Analysis of transcriptomic and proteomic profiles demonstrates the improvement of the MDCK cell function in a renal microfluidic biochip. Biotechnol Prog 28: 474-484.
14. Corlu A, Kneip B, Lhadi C, Leray G, Glaise D, Baffet G, Bourel D, Guguen-Guillouzo C. 1991. Plasma membrane protein is involved in cell contact-mediated regulation of tissue-specific genes in adult hepatocytes. J Cell Biol 115: 505-515.
15. Goren MP, Wright AK, Pratt CB, Pell FE. 1986. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2: 1219-1220.
16. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. 1999. Role of CYP2B6 and, CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 27: 533-541.
17. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc Nat Acad Sci 99: 15655-156600.
18. Gstraunthaler G, Pfaller W, Kotanko P. 1985. Biochemical characterization of renal epithelial cell cultures (LLC-PK1 and MDCK). Am J Physiol 248: F536-F544.
19. Hamberg P, Steeghs N, Loos W, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S. 2010. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: Results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Brit J Cancer 102: 1699-1706.
20. Hanly L, Chen N, Rieder M, Koren G. 2009. Ifosfamide nephrotoxicity in children: A mechanistic base for pharmacological prevention, Expert Opin Drug Saf 8: 155-168.
21. Highley MS, Schrijvers D, van Oosterom AT, Harper PG, Momerency G, Van Cauwenberghe K, Maes RAA, De Bruijn EA, Edelstein MB. 1997. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann Oncol 8: 1139-1144.
22. Ho P, Zimmerman K, Wexler L, Blaney S, Jarosinski P, Izraeli S, Balis F. 1995. A prospective evaluation of ifosfamide related nephrotoxicity in children and young adults. Cancer 76: 2557-2564.
23. Jingwen Z, Chan K, Muggia F. 1994. Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol 33: 391-398.
24. Khetani SR, Bhatia SN. 2008. Microscale human liver tissue for drug development. Nature Biotechnol 26: 120-126.
25. Lohr JW, Willsky GR, Acara MA. 1998. Renal drug metabolism. Pharmacol Rev 50: 107-141.
26. Lokiec F. 2006. Ifosfamide: Pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol 17(Suppl 4): iv33-iv36.
27. Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K. 2010. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Method 63: 59-68.
28. Mahler GJ, Esch MB, Glahn RP, Shuler ML. 2009. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnol Bioeng 104: 193-205.
29. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, Shen DD. 2005. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos 33: 1074-1081.
30. Midwoud PM, van Merema MT, Verpoorte E, Groothuis GMM. 2010. A micro fluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 10: 2778-2786.
31. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A micro fluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79: 1036-1044.
32. Prot JM, Aninat C, Griscom L, Razan F, Brochot C, Guguen Guillouzo C, Legallais C, Corlu A, Leclerc E. 2011a. Improvement of HepG2/C3a cell functions in a micro fluidic biochip. Biotechnol Bioeng 108: 1704-1715.
33. Prot JM, Briffaut AS, Letourneur F, Chafey P, Merlier F, Grandvalet Y, Legallais C, Leclerc E. 2011b. Integrated proteomic and transcriptomic investigation highlights original insight into paracetamol toxicity in liver biochip. PLoS ONE 6: 21268.
34. Schwerdt G, Gordjani N, Benesic A, Freudinger R, Wollny B, Antje K, Gekle M. 2006. Chloroacetaldehyde and acrolein induced death of human proximal tubule cells. Pediatr Nephrol 21: 60-67.
35. Springate JE. 1997. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 17: 75-79.
36. Springate J, Taub M. 2007. Ifosfamide toxicity in cultured proximal renal tubule cells. Pediatr Nephrol 22: 358-365.
37. Sung JH, Kam C, Shuler MJ. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10: 446-455.
38. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. 2007. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 12: 1351-1360.
39. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. 2003. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells J Am Soc Nephrol 14: 1-10.
40. Viravaidya K, Shuler ML. 2004. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 20: 590-597.
41. Walker GM, Zeringue HC, Beebe DJ. 2004. Microenvironment design considerations for cellular scale studies. Lab Chip 4: 91-97.
42. Wang X, Weisleder N, Collet C, Zhou J, Chu Y, Hirata Y, Zhao X, Pan Z, Brotto M, Cheng H, Ma J. 2005. Uncontrolled calcium sparks as dystrophic signal for mammalian skeletal muscle. Nat Cell Biol 7(5): 525-530.
43. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. 2000. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 68: 109-117.
44. Yu H, Meyvantsson I, Shkel IA, Beebe DJ. 2005. Diffusion dependent cell behavior in microenvironments. Lab Chip 5: 1089-1095.
45. Zamlauski-Tucker M, Morris M, Springate JE. 1998. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 129: 170-175.
46. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. 2005. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37: 611-703.